Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Exposure to Selective Serotonin Reuptake Inhibitors in Early Pregnancy and the Risk of Miscarriage

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Association between maternal weight gain and birth weight

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Quantification of biotin in plasma samples by column switching liquid chromatography - tandem mass spectrometry

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To study the association between paternal exposure to methotrexate within the 90-day period before pregnancy and congenital malformations and stillbirth in the offspring.

METHODS: We conducted a nationwide register study. Our cohort consisted of all live births in Denmark between 1997 and 2011 identified from the Medical Birth Registry. Methotrexate-exposed fathers were identified from the National Prescription Registry. From the national Hospital Registry we identified paternity, live births, and stillbirths as well as discharge diagnoses on congenital malformations.

RESULTS: We identified 849,676 live births with known paternity. There were 127 live births of methotrexate-exposed fathers. Of these, four (3.2%) had major malformations compared with 28,814 (3.4%) of the unexposed. The odds ratio (OR) for major congenital malformation among exposed fathers compared with unexposed was 0.93 (95% confidence interval [CI] 0.34-2.51) and when adjusted for year of birth, maternal age, educational length, household income, and parity, the adjusted OR was 1.01 (95% CI 0.37-2.74). There were no stillbirths in the methotrexate-exposed group compared with 2,541 (0.3%) in the unexposed group and no increased risk of preterm birth (adjusted OR 1.31, 95% CI 0.66-2.59) among the children from exposed fathers.

CONCLUSION: We found no association between paternal exposure to methotrexate within 90 days before pregnancy and congenital malformations, stillbirths, or preterm birth. Available data suggest that prepregnancy paternal methotrexate exposure should not be of major concern. Multinational recommendations should be changed accordingly.

Original languageEnglish
JournalObstetrics and Gynecology
Volume129
Issue number4
Pages (from-to)707-714
ISSN0029-7844
DOIs
Publication statusPublished - 1 Apr 2017

    Research areas

  • Journal Article

ID: 50109122